Sign In
Buy ABT
Abbott Laboratories Earnings Calls
| Release date | Jul 16, 2026 |
| EPS estimate | $1.28 |
| EPS actual | $1.31 |
| EPS Surprise | 2.34% |
| Revenue estimate | 12.519B |
| Revenue actual | 12.593B |
| Revenue Surprise | 0.587% |
| Release date | Apr 16, 2026 |
| EPS estimate | $1.14 |
| EPS actual | $1.15 |
| EPS Surprise | 0.88% |
| Revenue estimate | 11B |
| Revenue actual | 11.164B |
| Revenue Surprise | 1.49% |
| Release date | Jan 22, 2026 |
| EPS estimate | $1.50 |
| EPS actual | $1.50 |
| Revenue estimate | 11.8B |
| Revenue actual | 11.459B |
| Revenue Surprise | -2.89% |
| Release date | Oct 15, 2025 |
| EPS estimate | $1.30 |
| EPS actual | $1.30 |
| Revenue estimate | 11.39B |
| Revenue actual | 11.369B |
| Revenue Surprise | -0.182% |
Last 4 Quarters for Abbott Laboratories
Below you can see how ABT performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Oct 15, 2025 |
| Price on release | $129.45 |
| EPS estimate | $1.30 |
| EPS actual | $1.30 |
| Date | Price |
|---|---|
| Oct 09, 2025 | $133.31 |
| Oct 10, 2025 | $132.57 |
| Oct 13, 2025 | $131.38 |
| Oct 14, 2025 | $133.27 |
| Oct 15, 2025 | $129.45 |
| Oct 16, 2025 | $127.63 |
| Oct 17, 2025 | $128.54 |
| Oct 20, 2025 | $129.51 |
| Oct 21, 2025 | $127.54 |
| 4 days before | -2.90% |
| 4 days after | -1.48% |
| On release day | -1.41% |
| Change in period | -4.33% |
| Release date | Jan 22, 2026 |
| Price on release | $108.60 |
| EPS estimate | $1.50 |
| EPS actual | $1.50 |
| Date | Price |
|---|---|
| Jan 15, 2026 | $123.52 |
| Jan 16, 2026 | $121.76 |
| Jan 20, 2026 | $121.12 |
| Jan 21, 2026 | $120.73 |
| Jan 22, 2026 | $108.60 |
| Jan 23, 2026 | $107.42 |
| Jan 26, 2026 | $108.77 |
| Jan 27, 2026 | $108.23 |
| Jan 28, 2026 | $106.05 |
| 4 days before | -12.08% |
| 4 days after | -2.35% |
| On release day | -1.09% |
| Change in period | -14.14% |
| Release date | Apr 16, 2026 |
| Price on release | $95.46 |
| EPS estimate | $1.14 |
| EPS actual | $1.15 |
| EPS surprise | 0.88% |
| Date | Price |
|---|---|
| Apr 10, 2026 | $100.30 |
| Apr 13, 2026 | $100.65 |
| Apr 14, 2026 | $101.07 |
| Apr 15, 2026 | $101.50 |
| Apr 16, 2026 | $95.46 |
| Apr 17, 2026 | $96.83 |
| Apr 20, 2026 | $96.02 |
| Apr 21, 2026 | $92.75 |
| Apr 22, 2026 | $91.74 |
| 4 days before | -4.83% |
| 4 days after | -3.90% |
| On release day | 1.44% |
| Change in period | -8.53% |
| Release date | Jul 16, 2026 |
| Price on release | $98.82 |
| EPS estimate | $1.28 |
| EPS actual | $1.31 |
| EPS surprise | 2.34% |
| Date | Price |
|---|---|
| Jul 10, 2026 | $93.93 |
| Jul 13, 2026 | $92.12 |
| Jul 14, 2026 | $88.97 |
| Jul 15, 2026 | $89.27 |
| Jul 16, 2026 | $98.82 |
| Jul 17, 2026 | $100.67 |
| Jul 20, 2026 | $101.72 |
| Jul 21, 2026 | $99.68 |
| Jul 22, 2026 | $100.59 |
| 4 days before | 5.21% |
| 4 days after | 1.79% |
| On release day | 1.87% |
| Change in period | 7.09% |
Abbott Laboratories Earnings Call Transcript Summary of Q2 2026
Abbott reported Q2 2026 comparable sales growth of 4.8% and adjusted EPS of $1.31, beating the midpoint of guidance and consensus. Management reaffirmed full-year comparable sales guidance of +6.5% to +7.5% and raised full-year adjusted EPS guidance to $5.45–$5.60. Key operational highlights: diagnostics test volumes remain stable and served as a forward-looking indicator of resilient healthcare demand; Exact Sciences integration is on track with cancer diagnostics (Cologuard and related programs) showing strong growth and second-half acceleration expected from care-gap programs; nutrition showed sequential improvement driven by pediatric (WIC contract wins) and adult nutrition (pricing and new product SKUs); electrophysiology (EP) and other device franchises accelerated—Bolt 2.0 and Tactiflex Duo launches and international rollouts gained traction; continuous glucose monitoring (CGM) sales exceeded $2 billion (Q2 growth ~9.5%), Libre Duo (glucose + ketone sensor) obtained CE mark with international rollout planned and potential FDA submission pending; structural heart showed mixed performance with plans to improve U.S. commercial execution while pipeline programs (TAVR, mitral replacement) should drive longer-term growth. Profitability: adjusted gross margin expanded to 58.0% (up 100 bps year-over-year) driven by mix, Exact Sciences contribution, and margin initiatives. FX provided a modest tailwind in Q2 and is expected to be ~+1% for the full year. Management reiterated a strong pipeline with multiple near-term product launches and expects continued momentum into H2 2026, supporting EPS raise and potential for increased capital return given stronger cash generation.
